Financials data is unavailable for this security.
View more
Year on year Zimmer Biomet Holdings Inc grew revenues 6.55% from 6.94bn to 7.39bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 342.52% net income growth from 231.40m to 1.02bn.
| Gross margin | 71.78% |
|---|---|
| Net profit margin | 13.27% |
| Operating margin | 16.45% |
| Return on assets | 4.66% |
|---|---|
| Return on equity | 7.94% |
| Return on investment | 5.40% |
More ▼
Cash flow in USDView more
In 2023, Zimmer Biomet Holdings Inc increased its cash reserves by 10.67%, or 40.10m. The company earned 1.58bn from its operations for a Cash Flow Margin of 21.39%. In addition the company used 778.90m on investing activities and also paid 763.50m in financing cash flows.
| Cash flow per share | 9.45 |
|---|---|
| Price/Cash flow per share | 11.03 |
| Book value per share | 62.18 |
|---|---|
| Tangible book value per share | -3.86 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.29 |
|---|---|
| Quick ratio | 0.629 |
| Total debt/total equity | 0.458 |
|---|---|
| Total debt/total capital | 0.314 |
More ▼
Growth rates in USD
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 253.87%. Additionally, five year annualized dividend per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.71% |
|---|---|
| Div growth rate (5 year) | 0.00% |
| Payout ratio (TTM) | 19.88% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 99.58 |
More ▼
